Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I
receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine
and Dacarbazine. R-mabHD will be given once a week for eight weeks in a row. The ABVD
combination will be given once every other week for 12 treatments. The hypothesis is that
intervention with R-mabHD will lead to a quicker remission of Hodgkin's disease than the
intervention with a combination of ABVD.
Phase:
Phase 2
Details
Lead Sponsor:
American Scitech International
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC